利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.021 秒)

    MARKER GENES FOR DETERMINING RENAL TOXICITY
    1.
    发明公开
    MARKER GENES FOR DETERMINING RENAL TOXICITY 审中-公开
    标记基因检测肾毒性的

    公开(公告)号：EP1521847A2

    公开(公告)日：2005-04-13

    申请号：EP03762612.4

    申请日：2003-07-03

    申请人： Novartis AG ,  Novartis Pharma GmbH

    发明人： CHIBOUT, Salah-Dine ,  GRENET, Olivier ,  IMBERT, Georges ,  KEHREN, Jeanne ,  STÄDTLER. Frank ,  WOLFGANG, Curt, Douglas

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/158

    摘要： Methods are disclosed for fast and accurate readout of kidney toxicity before it occurs and before it is demonstrated by histopathology examination. Ultimately this approach shall allow earlier compound selection. The twelve genes identified, namely Calbindin-D28k, KIM-1, OPN, EGF, Clusterin, VEGF, OAT-K1, Aldolase A, Aldolase B, Podocin, Alpha-2u and C4, were grouped and ultimately can be assessed in the form of a kit using PCR, a high throughput technology, in order to characterize and rank new compounds according to their anticipated general kidney toxicity. Also disclosed are methods for identifying agents useful in the treatment of kidney disease, methods for monitoring the efficacy of a treatment for kidney disease and kidney-specific vectors including the sequences of the disclosed genes, and a method for identifying a candidate gene associated with a biological process including kidney function.

    USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS
    3.
    发明公开
    USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS 有权
    使用成纤维细胞生长因子破片

    公开(公告)号：EP1682665A2

    公开(公告)日：2006-07-26

    申请号：EP04797676.6

    申请日：2004-11-05

    申请人： Novartis AG ,  Novartis Pharma GmbH

    发明人： BOLLEKENS, Jacques ,  CHIBOUT, Salah-Dine ,  VONDERSCHER, Jacky ,  LEGAY, François ,  CORDIER, André ,  PAPOIAN, Ruben ,  SCHERER, Andreas

    IPC分类号： C12N15/19

    CPC分类号： C12N9/0073 ,  C07K2319/00 ,  G06Q50/22 ,  Y02A90/22

    摘要： A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants.

    USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS
    5.
    发明授权
    USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS 有权
    使用成纤维细胞生长因子破片

    公开(公告)号：EP1682665B1

    公开(公告)日：2011-04-27

    申请号：EP04797676.6

    申请日：2004-11-05

    申请人： Novartis AG

    发明人： BOLLEKENS, Jacques ,  CHIBOUT, Salah-Dine ,  VONDERSCHER, Jacky ,  LEGAY, François ,  CORDIER, André ,  PAPOIAN, Ruben ,  SCHERER, Andreas

    IPC分类号： C12N15/19

    CPC分类号： C12N9/0073 ,  C07K2319/00 ,  G06Q50/22 ,  Y02A90/22

    摘要： A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants.